djledda.de main
Nelze vybrat více než 25 témat Téma musí začínat písmenem nebo číslem, může obsahovat pomlčky („-“) a může být dlouhé až 35 znaků.
 
 

1007 řádky
77 KiB

  1. <html>
  2. <head><title>Estrogen and brain aging in men and women: Depression, energy, stress</title></head>
  3. <body>
  4. <h1>
  5. Estrogen and brain aging in men and women: Depression, energy, stress
  6. </h1>
  7. <p></p>
  8. <p>
  9. Although the incidence of Alzheimer's disease is 2 or 3 times as high among women as among men, there is a
  10. major campaign under way to convince the public that taking estrogen supplements will prevent the disease.
  11. Estrogen is now mainly promoted to prevent osteoporosis (another problem that is more common in women) and
  12. heart disease (which is more common in men).
  13. </p>
  14. <p>
  15. This substance, which came into medical use as "the female hormone" for the treatment of "female problems,"
  16. especially for improving fertility, and then for preventing fertility as the oral contraceptive, is now
  17. being aimed primarily at the post-reproductive population, for problems that are essentially unrelated to
  18. femininity. It is, in fact, being presented to the public as something to prevent major age-related
  19. conditions.
  20. </p>
  21. <p>
  22. Brain degeneration, like osteoporosis, takes years to develop. Analysis of letters written by young women,
  23. for example, showed limited mental functioning in those who many years later developed Alzheimer's disease,
  24. and young women who have small bones are the ones most likely to develop osteoporosis later.<strong>
  25. It seems clear that the course of degenerative aging processes is set in young adulthood (or even
  26. earlier), and that it is never too early to be concerned with correcting processes that are going in the
  27. wrong direction.</strong> (See Walker, et al., 1988, and Smith, et al., 1992.)
  28. </p>
  29. <p>
  30. In "The Biological Generality of Progesterone" (1979) I proposed that the life-long trajectory of energy
  31. production and longevity was strongly influenced by prenatal nutrition and progesterone. This idea was based
  32. on work by people such as Marion Diamond, who showed that prenatal progesterone enlarges the cortex of the
  33. brain, and that estrogen makes it smaller, and Leonell Strong, who showed that a treatment that lowered the
  34. estrogen function in a young mouse could produce cancer-free offspring for several generations. Strong's
  35. work was very encouraging, because it showed that biological problems that had been "bred in" over many
  36. generations could be corrected by some simple metabolic treatments.
  37. </p>
  38. <p>
  39. Seeing these profoundly toxic long-range effects of estrogen, which shaped the animal's growth, development,
  40. function, and even its heredity, made it important to learn how estrogen works, because such fundamental
  41. changes covering the whole range of biology, produced by a simple little molecule, promised to reveal
  42. interesting things about the nature of life.
  43. </p>
  44. <p>
  45. Aging is an energy problem, and in the brain, which has extremely high energy requirements, interference
  46. with the energy supply quickly causes cells to die.
  47. </p>
  48. <p>
  49. I believe that estrogen's "principle," in all of its actions, is to interfere with the respiratory mode of
  50. energy production. This is an integrating principle that explains estrogen's immediate, direct effects on
  51. cells and organisms, which aren't explained by the idea that it acts on the genes through a specific
  52. "estrogen receptor." (It's hard to imagine, for example, how the "estrogen receptor" doctrine could explain
  53. the fact that a single injection of estrogen can kill a large portion of brain cells.) It explains why
  54. estrogen causes cells to take up water, allowing calcium to enter, activating various enzymes and cell
  55. division. On the organismic level, it explains why estrogen mimics "shock," releasing histamine and
  56. activating the nervous and glandular stress response system. The inefficiency of metabolism which doesn't
  57. use oxygen in the normal way causes glucose to be used rapidly, and this in itself is enough to trigger the
  58. release of pituitary ACTH and adrenal cortisol. The ACTH, and related hormones, liberate free fatty acids,
  59. which cells take up instead of glucose, and this (in the so-called Randall cycle) further limits the body's
  60. ability to oxidize glucose.
  61. </p>
  62. <p>
  63. People have spoken of "cascades" in relation to the adrenal glucocorticoids (e.g., cortisol) and estrogen,
  64. leading to cell damage, but really both of these hormonal cascades have to be seen as part of a more general
  65. collapse of adaptive systems, as a result of both chronic and immediate inadequacies of energy production.
  66. </p>
  67. <p>
  68. <strong>Estrogen activates the adrenal stress reaction by way of the hypothalamus and pituitary, by direct
  69. actions on the adrenal glands, and by a variety of indirect effects, such as the increase of free fatty
  70. acids. It activates the excitotoxic glutamic acid pathway, and interferes with protective adenosine
  71. inhibition of nerves. It has both direct and indirect ways of promoting the formation of nitric oxide
  72. and carbon monoxide. These, and other estrogen-promoted factors, quickly and seriously interfere with
  73. mitochondrial respiration. Many of these effects contribute to increased intracellular calcium and free
  74. radical production, contributing to both the excitatory excess and the energy deficit.</strong>
  75. </p>
  76. <p>
  77. The biochemical details of these cascades are mainly interesting because they show how many different kinds
  78. of stress converge on a few physiological processess--mitochondrial energy production, cellular excitation,
  79. and intercellular communication--which, when damaged thousands of times, lead to the familiar states of old
  80. age. These few functions, damaged by an infinite variety of stresses, have their own complexly adaptive ways
  81. of deteriorating, producing the various degenerative diseases.
  82. </p>
  83. <p>
  84. This perspective brings dementia, heart failure, autoimmunity, immunodeficiency and other diseases of aging
  85. together, in ways that allow generalized therapeutic and preventive approaches.
  86. </p>
  87. <p>
  88. The antistress, antiestrogen approaches become fundamental to prevention of aging.
  89. </p>
  90. <p>
  91. The pro-estrogenic nature of the unsaturated fatty acids is probably the biggest barrier to the radical
  92. elimination of degenerative diseases. Various saturated fatty acids, including butyric, octanoic, and
  93. palmitic, have protective effects on mitochondrial respiration.
  94. </p>
  95. <p>
  96. <strong>Progesterone is the basic brain-protective antiestrogen. It works to protect the brain at many
  97. levels (preventing lipid peroxidation, exitotoxicity, nitric oxide damage, energy deficit, edema, etc.)
  98. and it promotes repair and recovery.</strong>
  99. </p>
  100. <p>
  101. Progesterone in most cases has effects opposite to estrogen's, improving mitochondrial energy production
  102. while preventing excessive excitation. Along with pregnenolone, progesterone is recognized as a neurosteroid
  103. with anti-excitotoxic actions, with the ability to promote repair and regeneration of the nervous system.
  104. (Roof, Stein, Faden; Schumacher, et al.; Baulieu.)
  105. </p>
  106. <p>
  107. The use of aspirin, which reduces inflammation and inhibits the formation of neurotoxic prostaglandins, is
  108. known to be associated with a lower incidence of Alzheimer's disease, and in other contexts, it offers
  109. protection against estrogen. Naloxone, the antiendorphin, has been found to reverse some of the cumulative
  110. effects of stress, restoring some pituitary and ovarian function, and it promotes recovery after brain
  111. injury<strong>;</strong> in a variety of ways, it corrects some of estrogen's toxic effects.
  112. </p>
  113. <p>
  114. Adenosine helps to maintain brain glycogen stores, which are lost in stress and aging. Vitamin B12 protects
  115. against nitric oxide, and improves alertness.
  116. </p>
  117. <p>
  118. Pyruvic acid has brain-protective effects, apparently through its decarboxylation (producing carbon dioxide)
  119. rather than through its use as an energy source, since other ketoacids are similarly protective. (The
  120. ketoacids occur in some natural foods.) The directly brain-protective effect of carbon dioxide offers many
  121. clues that should be interpreted in relation to estrogen's toxicity, since many of their effects on nerves
  122. are opposite. <strong>
  123. Estrogen blocks the production of energy while it stimulates nerve cells to use energy more rapidly, and
  124. carbon dioxide promotes the production of energy, while restraining the excitation which expends energy.
  125. </strong>
  126. The presence of carbon dioxide is an indicator of proper mitochondrial respiratory functioning.
  127. </p>
  128. <p>
  129. Pharmaceutical blockers of glutamic acid transmission, and of calcium and sodium uptake, prevent some
  130. deterioration following brain injury, but the most physiological way to protect against those toxic
  131. processes is to maintain metabolic energy at a high level. Magnesium, which is protective against excitatory
  132. damage and is a calcium antagonist, tends to be retained in proportion to the activity of thyroid hormone.
  133. </p>
  134. <p>
  135. As I have discussed previously, progesterone alone has brought people out of post-epileptic dementia and
  136. senile dementia, but it is reasonable to use a combined physiological approach, including thyroid.
  137. </p>
  138. <p>
  139. Besides providing new insights into biological energy and aging, the recognition that estrogen activates the
  140. stress hormone system--the pituitary-adrenal system--also provides clear insights into other problems, such
  141. as the polycystic ovary syndrome, hirsutism, adrenal hyperplasia, Cushing's disease, etc.
  142. </p>
  143. <p><h3>REFERENCES</h3></p>
  144. <p>
  145. [The references are clustered into groups, showing estrogen's indirect toxicity through its activation of
  146. the adrenal hormones, its direct brain-toxicity, and some of the interactions between these and fats, nitric
  147. oxide, etc.]
  148. </p>
  149. <p><em>.</em></p>
  150. <p>
  151. Stress 1996 Jul;1(1):1-19 <strong>
  152. Stress, Glucocorticoids, and Damage to the Nervous System: The Current State of Confusion.</strong>
  153. Sapolsky RM Department of Biological Sciences, Stanford University, Stanford, CA 94305. <strong>An extensive
  154. literature demonstrates that glucocorticoids (GCs), the adrenal steroids secreted during stress, can
  155. have a broad range of deleterious effects in the brain. The actions occur predominately, but not
  156. exclusively, in the hippocampus, a structure rich in corticosteroid receptors and particularly sensitive
  157. to GCs. The first half of this review considers three types of GC effects: a) GC-induced atrophy, in
  158. which a few weeks' exposure to high GC concentrations or to stress causes reversible atrophy of
  159. dendritic processes in the hippocampus; b) GC neurotoxicity where, over the course of months, GC
  160. exposure kills hippocampal neurons; c) GC neuroendangerment, in which elevated GC concentrations at the
  161. time of a neurological insult such as a stroke or seizure impairs the ability of neurons to survive the
  162. insult. The second half considers the rather confusing literature as to the possible mechanisms
  163. underlying</strong> these deleterious GC actions. Five broad themes are discerned: a) that GCs induce a
  164. metabolic vulnerability in neurons due to inhibition of glucose uptake; b) that GCs exacerbate various steps
  165. in a<strong>
  166. damaging cascade of glutamate excess, calcium mobilization and oxygen radical generation. In a review a
  167. number of years ago, I concluded that these two components accounted for the deleterious GC effects.
  168. Specifically, the energetic vulnerability induced by GCs left neurons metabolically compromised, and
  169. less able to carry out the costly task of containing glutamate, calcium and oxygen radicals. More recent
  170. work has shown this conclusion to be simplistic, and GC actions are shown to probably involve at least
  171. three additional components: c) that GCs impair a variety of neuronal defenses against neurologic
  172. insults; d) that GCs disrupt the mobilization of neurotrophins; e) that GCs have a variety of
  173. electrophysiological effects which can damage neurons.
  174. </strong>The relevance of each of those mechanisms to GC-induced atrophy, neurotoxicity and
  175. neuroendangerment is considered, as are the likely interactions among them.
  176. </p>
  177. <p>
  178. J Clin Endocrinol Metab 1996 Oct;81(10):3639-43 <strong>Short-term estradiol treatment enhances
  179. pituitary-adrenal axis and sympathetic responses to psychosocial stress in healthy young men.</strong>
  180. Kirschbaum C, Schommer N, Federenko I, Gaab J, Neumann O, Oellers M, Rohleder N, Untiedt A, Hanker J, Pirke
  181. KM, Hellhammer DH Center for Psychobiological, University of Trier, Germany. <strong>
  182. Evidence from animal studies and clinical observations suggest that the activity of the
  183. pituitary-adrenal axis is under significant influence of sex steroids. The present study investigated
  184. how a short term elevation of estradiol levels affects ACTH, cortisol, norepinephrine, and heart rate
  185. responses to mental stress in healthy men.
  186. </strong>In a double blind study, 16 men received a patch delivering 0.1 mg estradiol/day transdermally, and
  187. age- and body mass index-matched control subjects received a placebo patch. Twenty-four to 48 h later, they
  188. were exposed to a brief psychosocial stressor (free speech and mental arithmetic in front of an audience).
  189. In response to the psychosocial stressor, ACTH, cortisol, norepinephrine, and heart rate were increased in
  190. both experimental groups (all P &lt; 0.0001). However, the<strong>
  191. estradiol-treated subjects showed exaggerated peak ACTH (P &lt; 0.001) and cortisol (P &lt; 0.002)
  192. responses compared to the placebo group. Also, the norepinephrine area under the response curve was
  193. greater in the estradiol group
  194. </strong>
  195. (P &lt; 0.05). Although heart rate responses differences failed to reach statistical significance, they,
  196. too, tended to be larger in the estradiol group. Neither mood ratings before or after the stressor, nor
  197. ratings of the perception of the stressor could explain the observed endocrine response differences. In
  198. conclusion, <strong>short term estradiol administration resulted in hyperresponses of the pituitary-adrenal
  199. axis and norepinephrine to psychosocial stress in healthy young men independent of psychological
  200. effects,
  201. </strong>as assessed in this study.
  202. </p>
  203. <p>
  204. J Appl Physiol 1996 Mar;80(3):931-9 <strong>
  205. Treadmill exercise training and estradiol increase plasma ACTH and prolactin after novel
  206. footshock.</strong> White-Welkley JE, Warren GL, Bunnell BN, Mougey EH, Meyerhoff JL, Dishman RK "We
  207. examined whether rats that were treadmill exercise trained (Tr) or chronically immobilized (CI) had similar
  208. responses by the hypothalamic-pituitary-adrenal (HPA) cortical axis to acute stress and whether the HPA
  209. responses interacted with the hypothalamic-pituitary-gonadal (HPG) axis." <strong>"[ACTH] and
  210. [prolactin</strong>] after<strong>
  211. footshock were higher in Tr rats with E2 compared with CI and sedentary rats without E2;</strong>
  212. recovery levels for sedentary animals were higher after Run compared with Im. The elevation in
  213. [corticosterone] from minute 1 to 15 of recovery was higher after the familiar Run and Im conditions. Our
  214. findings are consistent with an increased responsiveness of the HPA axis to novel footshock after treadmill
  215. exercise training that is additionally modulated by the HPG axis."
  216. </p>
  217. <p>
  218. Endocrinology 1992 Sep;131(3):1261-9. <strong>
  219. Chronic estrogen-induced alterations in adrenocorticotropin and corticosterone secretion, and
  220. glucocorticoid receptor-mediated functions in female rats.</strong> Burgess LH, Handa RJ "The effect of
  221. estrogen (E) on the hypothalamic-pituitary-adrenal axis was investigated in female Sprague-Dawley rats."
  222. "...the ACTH and CORT secretory responses to ether stress could be suppressed by exogenous RU 28362 (a
  223. specific glucocorticoid receptor agonist; 40 micrograms/100 g BW for 4 days) in OVX controls (P less than
  224. 0.05), <strong>but not in E-treated animals.</strong> These data suggest that E can impair glucocorticoid
  225. receptor-mediated delayed or slow negative feedback." "Thus, E<strong>
  226. treatment results in a loss of the glucocorticoid receptor's ability to autoregulate; this suggests that
  227. E may cause a functional impairment of the glucocorticoid receptor even though receptor binding appears
  228. normal. These findings suggest that hyperactivation of the hypothalamic-pituitary-adrenal axis after
  229. stress in E-treated rats is due in part to impaired glucocorticoid receptor-mediated slow negative
  230. feedback."
  231. </strong>
  232. </p>
  233. <p>
  234. Am J Physiol 1994 Jul;267(1 Pt 1):E32-8 <strong>Lesions of hypothalamic paraventricular nuclei do not
  235. prevent the effect of estradiol on energy and fat balance.</strong>
  236. Dagnault A, Richard D. <strong>"Plasma levels of corticosterone and ACTH were higher in E2-treated rats than
  237. in animals receiving the placebo treatment. The present results provide evidence that the hypothalamic
  238. PVH is not an essential neuroanatomical structure in the effects of E2 on energy and fat balances."
  239. </strong>
  240. </p>
  241. <p>
  242. Fertil Steril 1994 Oct;62(4):738-43 <strong>
  243. Ovarian suppression reduces clinical and endocrine expression of late-onset congenital adrenal
  244. hyperplasia due to 21-hydroxylase deficiency.</strong>
  245. Carmina E, Lobo RA "OBJECTIVE: To determine the effectiveness of GnRH-agonist (GnRH-a) treatment in women
  246. with late onset congenital adrenal hyperplasia." "CONCLUSIONS: Suppression of the ovary with GnRH-a
  247. treatment was beneficial in these patients with late-onset congenital adrenal hyperplasia. An ovarian
  248. influence on the clinical and biochemical findings of the disorder is suggested."
  249. </p>
  250. <p>
  251. Life Sci 1995;57(9):833-7. <strong>
  252. Effects of sex hormones on the steroidogenic activity of dispersed adrenocortical cells of the rat
  253. adrenal cortex.</strong> Nowak KW, Neri G, Nussdorfer GG, Malendowicz LK "The effect of 17
  254. beta-estradiol and testosterone on glucocorticoid secretion were studied in vitro by using dispersed inner
  255. adrenocortical cells obtained from gonadectomized female and male rats. Independently of the sex of animals,
  256. estradiol enhanced basal, but not ACTH-stimulated corticosterone (B) secretion; conversely, testosterone
  257. inhibited ACTH-stimulated, but not basal B output." "Testosterone inhibited by about 30% ACTH-stimulated
  258. PREG production and by about 54% total post-PREG secretion (B was decreased to 56% of the control value, and
  259. other steroid hormones were below the limit of sensitivity of our assay system). These findings indicate
  260. that sex hormones directly affect rat adrenocortical secretion,<strong>
  261. mainly by acting on the rate-limiting step of steroidogenesis (i.e. the conversion of cholesterol to
  262. PREG); moreover, they suggest that testosterone is also able depress the activity of the enzymes
  263. operating distally to cholesterol side-chain cleavage."
  264. </strong>
  265. </p>
  266. <p>
  267. J Endocrinol 1995 Feb;144(2):311-21 <strong>
  268. The influence of ovarian steroids on hypothalamic-pituitary-adrenal regulation in the female
  269. rat.</strong> Carey MP, Deterd CH, de Koning J, Helmerhorst F, de Kloet ER "The present study examined
  270. the association between hypothalamic- pituitary-adrenal (HPA) and hypothalamic-pituitary-ovarian axes. HPA
  271. activity determined by plasma levels of adrenocorticotropin (ACTH) and corticosterone (B) was assessed in
  272. intact female rats as a function of oestrous cycle stage under resting conditions and after exposure to a 20
  273. min restraint stress. To delineate the roles of oestradiol and progesterone in HPA axis modulation, plasma
  274. concentrations of ACTH and B were determined in ovariectomised (OVX) animals treated with oestradiol and/or
  275. progesterone under resting conditions and during exposure to the stress of a novel environment. The effects
  276. of these steroid treatments on the transcription and/or binding properties of the two corticosteroid
  277. receptors, the mineralocorticoid (MR) and glucocorticoid (GR) receptors, were also examined in hippocampal
  278. tissue, (i) Fluctuations in basal and<strong>
  279. stress-induced plasma ACTH and B concentrations were found during the oestrous cycle with highest levels
  280. at late pro-oestrus. (ii) In OVX steroid-replaced animals, basal and stress-induced activity was
  281. enhanced in oestradiol and oestradiol plus progesterone-treated animals compared with OVX controls."
  282. </strong>
  283. "In conclusion, we find that sex steroids modulate HPA activity and<strong>
  284. suggest that the observed effects of these steroids on hippocampal MR may underlie their concerted
  285. mechanism of action in inducing an enhanced activity at the period of late pro-oestrus."
  286. </strong>
  287. </p>
  288. <p>
  289. J Clin Endocrinol Metab 1995 Feb;80(2):603-7 <strong>The impact of estrogen on adrenal androgen sensitivity
  290. and secretion in polycystic ovary syndrome.</strong> Ditkoff EC, Fruzzetti F, Chang L, Stancyzk FZ, Lobo
  291. RA <strong>"Adrenal hyperandrogenism is a common feature of patients with polycystic ovary syndrome (PCO).
  292. </strong>
  293. This may be due to enhanced adrenal sensitivity to ACTH.<strong>
  294. Because enhanced ovarian androgen secretion does not appear to explain this phenomenon, we explored the
  295. role of estrogen in inducing enhanced adrenal sensitivity, in that a state of relative hyperestrogenism
  296. exists in PCO."
  297. </strong>"Steroid ratio<strong>
  298. responses to oCRH suggested that 17,20-desmolase activity (delta maximum change in the ratio of
  299. A4/17-hydroxyprogesterone) was lowered with estrogen suppression and increased again after transdermal
  300. E2 administration."</strong> "In conclusion, these data provide<strong>
  301. evidence that estrogen is at least one factor that influences adrenal androgen sensitivity in PCO and
  302. may help explain the frequent finding of adrenal hyperandrogenism in this syndrome."
  303. </strong>
  304. </p>
  305. <p>
  306. Endocrinology 1993 Nov;133(5):2284-91 <strong>
  307. Estrogen and hydroxysteroid sulfotransferases in guinea pig adrenal cortex: cellular and subcellular
  308. distributions.</strong> Whitnall MH, Driscoll WJ, Lee YC, Strott CA "The high concentration of EST
  309. immunoreactivity in nuclei suggests that EST may play a role in modulating the<strong>
  310. ability of active estrogens to regulate gene expression in ACTH-responsive cells. The distribution of
  311. HST labeling suggests that sulfonation of adrenocortical 3-hydroxysteroids takes place largely within
  312. smooth endoplasmic reticulum in the zona reticularis in adult guinea pigs."
  313. </strong>
  314. </p>
  315. <p>
  316. J Clin Endocrinol Metab 1993 Sep;77(3):754-8. <strong>Interaction of insulin-like growth factor-II and
  317. estradiol directs steroidogenesis in the human fetal adrenal toward dehydroepiandrosterone sulfate
  318. production.
  319. </strong>
  320. Mesiano S, Jaffe RB
  321. </p>
  322. <p>
  323. J Clin Endocrinol Metab 1993 Aug;77(2):494-7. <strong>Estradiol stimulates cortisol production by adrenal
  324. cells in estrogen-dependent primary adrenocortical nodular dysplasia.</strong>
  325. Caticha O, Odell WD, Wilson DE, Dowdell LA, Noth RH, Swislocki AL, Lamothe JJ, Barrow R. Adrenal glands from
  326. a patient with ACTH-independent Cushing's syndrome, whose symptoms worsened during pregnancy and oral
  327. contraceptive use, were cultured in different concentrations of estradiol. Estradiol stimulated cortisol
  328. secretion in a dose-response manner in the absence of ACTH." . "This is the first description of estradiol
  329. stimulation of cortisol production by cultured adrenal cells in ACTH-independent Cushing's syndrome."
  330. </p>
  331. <p>
  332. Endocrinology 1992 Nov;131(5):2430-6 <strong>
  333. Effects of gonadectomy and sex hormone therapy on the endotoxin-stimulated hypothalamo-pituitary-adrenal
  334. axis: evidence for a neuroendocrine-immunological sexual dimorphism.</strong> Spinedi E, Suescun MO,
  335. Hadid R, Daneva T, Gaillard RC "Bacterial lipopolysaccharide (LPS) stimulates the
  336. hypothalamo-pituitary-adrenal axis by a mechanism involving the release of cytokines, which activate the
  337. CRH-ACTH system and, as a result, increase glucocorticoid secretion. <strong>
  338. In the present study we investigated the possibility that endogenous sex hormones modulate the in vivo
  339. endotoxin-stimulated adrenal and immune responses in adult BALB/c mice."</strong> "Our results indicate
  340. that 1)<strong>
  341. randomly cycling female mice have significantly more pronounced corticosterone secretion than males 2 h
  342. after endotoxin
  343. </strong>
  344. injection, although the tumor necrosis factor responses were similar....".
  345. </p>
  346. <p>
  347. J Neurosci Res 1995 Oct 1;42(2):228-35 <strong>
  348. Activation of the hypothalamo-anterior pituitary corticotropin- releasing hormone, adrenocorticotropin
  349. hormone and beta-endorphin systems during the estradiol 17 beta-induced plasma LH surge in the
  350. ovariectomized monkey.</strong> Kerdelhue B, Jones GS, Gordon K, Seltman H, Lenoir V, Melik
  351. Parsadaniantz S, Williams RF, Hodgen GD. "These results suggest that there<strong>
  352. may be a marked activation of the hypothalamo-anterior pituitary-adrenal axis during the negative and
  353. positive feedback phases of the E2B-induced LH surge in the ovariectomized monkey."
  354. </strong>
  355. </p>
  356. <p>
  357. Biol Reprod 1995 Nov;53(5):996-1002 <strong>
  358. Activation of the baboon fetal pituitary-adrenocortical axis at midgestation by estrogen: responsivity
  359. of the fetal adrenal gland to adrenocorticotropic hormone in vitro.</strong> Berghorn KA, Albrecht ED,
  360. Pepe G.J.
  361. </p>
  362. <p>
  363. Fertil Steril 1996 May;65(5):950-3 <strong>
  364. Ovarian hyperstimulation augments adrenal dehydro- epiandrosterone sulfate secretion.</strong> Casson
  365. PR, Kristiansen SB, Umstot E, Carson SA, Buster JE.
  366. </p>
  367. <p>
  368. Hinyokika Kiyo 1997 Apr;43(4):275-8 <strong>
  369. [A case of concurrent bilateral adrenocortical adenoma causing Cushing's syndrome].</strong> Koga F,
  370. Sumi S, Umeda H, Maeda S, Honda M, Hosoya Y, Yano M, Konita A, Suzuki S, Yoshida K. "All 14 previously
  371. reported cases of bilateral adrenocortical adenoma (BAA) causing Cushing's syndrome as well as the present
  372. case were<strong>
  373. concurrent and dominant in females of reproductive age. This suggests that some cofactors other than
  374. ACTH, such as estrogen, contribute to the pathogenesis of BAA."
  375. </strong>
  376. </p>
  377. <p>
  378. Endocrinology 1991 Nov;129(5):2503-11 <strong>
  379. Variations in the hypothalamic-pituitary-adrenal response to stress during the estrous cycle in the
  380. rat.</strong> Viau V, Meaney MJ. <strong>"In cycling rats, we found significantly higher peak ACTH (P
  381. less than 0.01) and B (P less than 0.05) responses to stress during proestrus
  382. </strong>
  383. compared to the estrous and diestrous phases." "In response to<strong>
  384. stress, ACTH levels were higher (P less than 0.01) in the E' group compared to the EP' and O' groups.
  385. </strong>
  386. Although the peak B response was similar in all groups, the E' and EP' groups secreted more B after the
  387. termination of stress than did the O' group. Within the 20 min stress period,<strong>
  388. ACTH levels in the E' group were significantly (P less than 0.05) higher at 5, 10, and 15 min after the
  389. onset of stress, compared to the EP' and O' groups. Plasma B levels were significantly higher in the E'
  390. group at 5 and 10 min (P less than 0.05 and P less than 0.01, respectively) compared to the EP' and O'
  391. group. beta-endorphin-like immunoreactive responses to restraint stress were also significantly higher
  392. in the E' group compared to the EP' (P less than 0.05) and O'</strong> (P less than 0.01) groups. In
  393. contrast to the effect seen at 24 h, ACTH responses to stress 48 h after E2 injection in the E' group were
  394. comparable to O' animals. There was no effect of E2 on ACTH clearance, whereas B clearance was enhanced in
  395. E' treated animals vs. O'-treated animals. These results indicate that the HPA axis in the female rat is
  396. most sensitive to stress during proestrous. Such enhanced HPA responses to stress are limited to the early
  397. portion of proestrous, <strong>as progesterone appears to inhibit the facilitatory effects of estrogen on
  398. ACTH release during stress.
  399. </strong>
  400. Taken together, these results suggest an ovarian influence on both activational and inhibitory components of
  401. HPA activity."
  402. </p>
  403. <p>
  404. Semin Reprod Endocrinol 1997 May;15(2):137-57 <strong>Adrenal involvement in polycystic ovary syndrome.
  405. </strong>
  406. Gonzalez F. "Whereas 17,20 lyase hyperactivity diagnosed by defined criteria in response to pharmacological
  407. ACTH may be an intrinsic genetic defect, <strong>increases in 17,20 lyase activity and adrenal androgen
  408. hyper-responsiveness to ACTH in response to physiological ACTH may be promoted by the functional
  409. elevation of estrogen of ovarian origin in PCOS.
  410. </strong>The latest in vitro data suggest the estrogen may elicit its effect on the adrenal cortex through a
  411. receptor mediated mechanism."
  412. </p>
  413. <p>
  414. Metabolism 1997 Aug;46(8):902-7. <strong>
  415. Mild adrenal and ovarian steroidogenic abnormalities in hirsute women without hyperandrogenemia: does
  416. idiopathic hirsutism exist?</strong> Escobar-Morreale HF, Serrano-Gotarredona J, Garcia-Robles R, Sancho
  417. J, Varela C <strong>"Basal and ACTH-stimulated 17OHP and delta 4-A, and stimulated DHEA concentrations were
  418. reduced with ovarian suppression,</strong> but their net increment and ratio to the increase of F in
  419. response to ACTH remained unchanged, <strong>
  420. reflecting the ovarian contribution to the secretion of these steroids."</strong>.
  421. </p>
  422. <p>
  423. Am J Physiol 1997 Apr;272(4 Pt 2):R1128-34.<strong>
  424. Modulation of ovine fetal adrenocorticotropin secretion by androstenedione and 17beta-estradiol.</strong
  425. > Saoud CJ, Wood CE "Parturition in sheep is initiated by increases in activity of the fetal
  426. hypothalamic-pituitary-adrenal axis. We<strong>
  427. have previously reported that cortisol negative feedback efficacy is decreased at the end of gestation.
  428. </strong>The present study was designed to test the hypothesis that<strong>
  429. increasing plasma estrogen and/or androgen concentrations in the fetus might increase plasma
  430. adrenocorticotropic hormone (ACTH) concentration, either by stimulating ACTH secretion or by altering
  431. the negative feedback</strong>
  432. effect of cortisol on ACTH." "We conclude that increased fetal cortisol and ACTH secretion at the end of
  433. gestation may be due to the combined effects of the gonadal steroids in that<strong>
  434. estradiol increases basal plasma ACTH secretion while androstenedione reduces cortisol negative feedback
  435. efficacy."
  436. </strong>
  437. </p>
  438. <p>
  439. J Clin Endocrinol Metab 1998 Sep;83(9):3083-8. <strong>
  440. Menstrual abnormalities in women with Cushing's disease are correlated with hypercortisolemia rather
  441. than raised circulating androgen levels.</strong> Lado-Abeal J, Rodriguez-Arnao J, Newell-Price JD,
  442. Perry LA, Grossman AB, Besser GM, Trainer PJ.
  443. </p>
  444. <p>
  445. Eur J Endocrinol 1998 Apr;138(4):430-5. <strong>
  446. Hypothalamo-pituitary-adrenal axis and adrenal function before and after ovariectomy in premenopausal
  447. women.</strong> De Leo V, la Marca A, Talluri B, D'Antona D, Morgante G <strong>
  448. The hypothalamo-pituitary-adrenal (HPA) axis is modulated by sex hormones. Few data exist on the
  449. relation between acute estrogen deficit and HPA axis response to corticotropin-releasing hormone
  450. (CRH).</strong> The effects of a sudden drop in estradiol levels on basal and CRH-stimulated levels of
  451. ACTH, cortisol, testosterone, androstenedione and 17-hydroxyprogesterone (17-OHP) were assessed in nine
  452. premenopausal women (44-48 years of age), before and after ovariectomy. The CRH test was performed before
  453. and 8 days after ovariectomy.<strong>
  454. A significant reduction in ACTH and adrenal steroids but not in cortisol response to CRH was observed
  455. after ovariectomy.
  456. </strong>
  457. The ratio of deltamax androstenedione/17-OHP after CRH stimulation was substantially the same before and
  458. after ovariectomy, whereas <strong>deltamax 17-OHP/cortisol was significantly lower in
  459. ovariectomized</strong> women showing increased 21- and 11beta-hydroxylase activity. The results show
  460. that the acute estrogen deficit induces changes in the HPA xis characterized by <strong>reduced stimulated
  461. secretion of ACTH and steroids</strong> but normal stimulated cortisol production.
  462. </p>
  463. <p>
  464. Biokhimiia 1987 Sep;52(9):1501-11 <strong>
  465. [Activation of lipolysis and ketogenesis in tumor-bearing animals as a reflection of chronic stress
  466. states].</strong> [Article in Russian] Chekulaev VA, Shelepov VP, Pasha-zade GR, Shapot VS In order to
  467. elucidate the peculiarities of brain metabolism in tumour-bearing organisms, the arterio-venous (A-V)
  468. content of glucose, acetoacetate (Ac-Ac), beta-hydroxybutyrate (beta-HB) and non-esterified fatty acids
  469. (NEFA) in growing Zajdela ascite hepatoma (ZAH) and solid hepatoma 27 (H-27) was compared. Analysis of
  470. metabolic patterns of healthy, starving and fed recipients (ZAH and H-27) revealed the inadequacy of the
  471. concepts on anorexia as being the cause of carbohydrate-lipid metabolic disturbances. In tumour-bearing
  472. organisms <strong>lipolysis and ketogenesis reflect the tumour-induced chronic stress.</strong> Absorption
  473. of beta-HB and release of Ac-Ac by brain were observed at all stages of malignant growth. <strong>This is
  474. probably due to a partial switch-over of brain metabolism to non-carbohydrate energy sources.
  475. </strong>Besides, certain stages of tumour growth are associated with <strong>active assimilation of NEFA by
  476. brain.</strong> A correlation between the A-V difference with respect to glucose and Ac-Ac as well as
  477. between the glucose and NEFA contents was established. It was assumed that the A-V difference in glucose is
  478. the main regulator of ketone body metabolism.
  479. </p>
  480. <p>
  481. R. Sanchez Olea, et al., <strong>
  482. "Inhibition by polyunsaturated fatty acids of cell volume regulation and osmolyte fluxes in
  483. astrocytes,"</strong> Amer. J. of Physiology--cell physiology 38(1), C96-C102, 1995. <strong>"...potent
  484. blockers of regulatory volume decrease and of the swelling-activated efflux of taurine,
  485. D-aspartate,</strong> inositol, and I-125 (used as marker of Cl). <strong>
  486. ...oleic and ricinoleic acids and saturated fatty acids were ineffective." "...polyunsaturated fatty
  487. acids directly inhibit the permeability pathways correcting cell volume after swelling in cultured
  488. astrocytes."</strong>
  489. </p>
  490. <p>
  491. P. H. Chan and R. A. Fishman, "<strong>Brain edema: Induction in cortical slices by polyunsaturated fatty
  492. acids</strong>," Science 201, 358-369, 1978. "This cellular edema was specific, since <strong>
  493. neither saturated fatty acids nor a fatty acid containing a single double bond had such effect</strong
  494. >."
  495. </p>
  496. <p>
  497. Endocrinology 1992 Aug;131(2):662-8 <strong>Estradiol selectively regulates agonist binding sites on the
  498. N-methyl-D-aspartate receptor complex in the CA1 region of the hippocampus.</strong> Weiland NG.
  499. Laboratory of Neuroendocrinology, Rockefeller University. <strong>
  500. "Estradiol alters cognitive function and lowers the threshold for seizures in women and laboratory
  501. animals. Both of these activities are modulated by the excitatory neurotransmitter glutamate in the
  502. hippocampus. To assess the hypothesis that estradiol increases the sensitivity of the hippocampus to
  503. glutamate activation by increasing glutamate binding sites, the densities of N-methyl-D-aspartate (NMDA)
  504. agonist sites...."</strong> "Two days of estradiol treatment increased the density of NMDA agonist, but
  505. not of competitive nor noncompetitive NMDA antagonist binding sites exclusively in the CA1 region of the
  506. hippocampus." <strong>
  507. "The increase in NMDA agonist sites with ovarian hormone treatment should result in an increase in the
  508. sensitivity of the hippocampus to glutamate activation which may mediate some of the effects of
  509. estradiol on learning and epileptic seizure activity."</strong>
  510. </p>
  511. <p>
  512. J Neurochem 1994 Sep;63(3):953-62 <strong>
  513. Corticosterone regulates heme oxygenase-2 and NO synthase transcription and protein expression in rat
  514. brain.</strong> Weber CM, Eke BC, Maines MD.<strong>"We suggest that glucocorticoid-mediated deficits in
  515. hippocampal functions may reflect their negative effect on messenger-generating systems."
  516. </strong>
  517. </p>
  518. <p>
  519. Gen Pharmacol 1993 Nov;24(6):1383-6 <strong>
  520. Changes in microtubular tau protein after estrogen in a cultured human neuroblastoma cell line.</strong>
  521. Lew GM. <strong>"4. The estrogen (10(-7) M) also caused a 31% reduction in the total number of
  522. cells."</strong>
  523. </p>
  524. <p>
  525. Rodriguez, P; Fernandez-Galaz, C; Tejero, A. <strong>Controlled neonatal exposure to estrogens: A suitable
  526. tool for reproductive aging studies in the female rat.</strong>
  527. Biology of Reproduction, v.49, n.2, (1993): 387-392.
  528. </p>
  529. <p>
  530. O'Rourke, M T; Lipson, S F; Ellison, P T. <strong>Ovarian function in the latter half of the reproductive
  531. lifespan.</strong> American Journal of Human Biology, v.8, n.6, (1996): 751-759.
  532. </p>
  533. <p>
  534. Schumacher, M; Robel, P; Baulieu, E-E. <strong>Development and regeneration of the nervous system: A role
  535. for neurosteroids.</strong> Developmental Neuroscience, v.18, n.1-2, (1996): 6-21.
  536. </p>
  537. <p>
  538. Life Sci 1996;58(17):1461-7 <strong>The endogenous estrogen metabolite 2-methoxyestradiol induces apoptotic
  539. neuronal cell death in vitro.</strong> Nakagawa-Yagi Y, Ogane N, Inoki Y, Kitoh N. "We examined the
  540. effects of 2-methoxyestradiol, a metabolite of estradiol, on cell death in retinoic acid (RA)-differentiated
  541. neuroblastoma SH-SY5Y cell cultures. <strong>Cell death was induced by 2-methoxyestradiol in a
  542. concentration- dependent manner</strong>."<strong> [</strong>Provides evidence]<strong>
  543. "...for an endogenous neuroactive steroid metabolite in the etiology of some neurodegenerative
  544. diseases."</strong>
  545. </p>
  546. <p>
  547. Recent Prog Horm Res 1997;52:279-303 <strong>
  548. Aging of the female reproductive system: a window into brain aging.</strong>
  549. Wise PM, Kashon ML, Krajnak KM, Rosewell KL, Cai A, Scarbrough K, Harney JP, McShane T, Lloyd JM, Weiland NG
  550. <strong>"The menopause marks the permanent end of fertility in women. It was once thought that the
  551. exhaustion of ovarian follicles was the single, most important explanation for the transition to the
  552. menopause. Over the past decade, this perception has gradually changed with the realization that there
  553. are multiple pacemakers of reproductive senescence. We will present evidence that lends credence to the
  554. hypothesis that the central nervous system is a critical pacemaker of reproductive aging and that
  555. changes at this level</strong> contribute to the timing of the menopause."
  556. </p>
  557. <p>
  558. Neuroendocrinology 1989 Nov;50(5):605-612 <strong>
  559. N-methyl-aspartic acid lesions of the arcuate nucleus in adult C57BL/6J mice: a new model for
  560. age-related lengthening of the estrous cycle.</strong>
  561. May PC, Kohama SG, Finch CE. "We report a new effect of the excitotoxin N-methyl-aspartic acid (NMA) on
  562. adult mice. Besides confirming cell loss in the arcuate nucleus of animals treated as adults, we also
  563. observed lengthened estrous cycles. Cycling female C57BL/6J mice were treated with subcutaneous injections
  564. of NMA and estrous cycles monitored for 30 days. NMA treatment lengthened average estrous cycle length by 1
  565. day, to 5.6 days."<strong>
  566. "Consistent with the regional pattern of cell loss, little specific binding of any glutamatergic ligand
  567. was observed in the VMN. NMA caused weight gain in all age groups." "The transition from 4-day to 5- and
  568. 6-day estrous cycles produced by NMA treatment mimics the early age-related changes in estrous cycle
  569. patterns in rodents."</strong> This new model will be useful in analyzing the contributions of
  570. neuroendocrine changes in the arcuate nucleus to reproductive senescence."
  571. </p>
  572. <p>
  573. <strong>Pathologic effect of estradiol on the hypothalamus.</strong> Brawer JR; Beaudet A; Desjardins GC;
  574. Schipper HM. Biol Reprod, 1993 Oct, 49:4, 647-52. "In addition to its multiple physiological actions, we
  575. have shown that estradiol is also selectively cytotoxic to beta-endorphin neurons in the hypothalamic
  576. arcuate nucleus. The mechanism underlying this neurotoxic action appears to involve the conversion of
  577. estradiol to catechol estrogen and subsequent oxidation to o-semiquinone free radicals. The
  578. estradiol-induced loss of beta-endorphin neurons engenders a compensatory increment in mu opioid binding in
  579. the medial preoptic area rendering this region supersensitive to residual beta-endorphin or to other
  580. endogenous opioids. The consequent persistent opioid inhibition results in a cascade of neuroendocrine
  581. deficits that are ultimately expressed as a chronically attenuated plasma LH pattern to which the ovaries
  582. respond by becoming anovulatory and polycystic. This neurotoxic action of estradiol may contribute to a
  583. number of reproductive disorders in humans and in animals in which aberrant hypothalamic function is a major
  584. component."
  585. </p>
  586. <p>
  587. <strong>Vitamin E protects hypothalamic beta-endorphin neurons from estradiol neurotoxicity</strong>.
  588. Desjardins GC; Beaudet A; Schipper HM; Brawer JR. Endocrinology, 1992 Nov, 131:5, 2482-4 <strong>"Estradiol
  589. valerate (EV) treatment has been shown to result in the destruction of 60% of beta-endorphin neurons in
  590. the hypothalamic arcuate nucleus."</strong>
  591. </p>
  592. <p>
  593. <strong>Estrogen-induced hypothalamic beta-endorphin neuron loss: a possible model of hypothalamic
  594. aging.</strong>
  595. Desjardins GC; Beaudet A; Meaney MJ; Brawer JR. Exp Gerontol, 1995 May-Aug, 30:3-4, 253-67 Over the course
  596. of normal aging, all female mammals with regular cycles display an irreversible arrest of cyclicity at
  597. mid-life. Males, in contrast, exhibit gametogenesis until death.<strong>
  598. Although it is widely accepted that exposure to estradiol throughout life contributes to reproductive
  599. aging, a unified hypothesis of the role of estradiol in reproductive senescence has yet to
  600. emerge.</strong>
  601. Recent evidence derived from a rodent model of chronic estradiol-mediated accelerated reproductive
  602. senescence now suggests such a hypothesis. It has been shown that chronic estradiol exposure results in the
  603. <strong>
  604. destruction of greater than 60% of all beta-endorphin neurons in the arcuate nucleus
  605. </strong>while leaving other neuronal populations spared. This loss of opioid neurons is prevented by
  606. treatment with antioxidants indicating that it results from <strong>estradiol-induced formation of free
  607. radicals. Furthermore, we have shown that this beta-endorphin cell loss is followed by a compensatory
  608. upregulation of mu opioid receptors in the vicinity of LHRH cell bodies.</strong> The increment in mu
  609. opioid receptors presumably renders the opioid target cells supersensitive to either residual beta-endorphin
  610. or other endogenous mu ligands, such as met-enkephalin, thus resulting in chronic opioid <strong>suppression
  611. of the pattern of LHRH release, and subsequently that of LH.</strong> Indeed, prevention of the
  612. neuroendocrine effects of estradiol by antioxidant treatment also <strong>
  613. prevents the cascade of neuroendocrine aberrations resulting in anovulatory acyclicity.</strong> The
  614. loss of beta-endorphin neurons along with the paradoxical opioid supersensitivity which ensues, provides a
  615. unifying framework in which to interpret the diverse features that characterize the reproductively senescent
  616. female.
  617. </p>
  618. <p>
  619. <strong>The 21-aminosteroid antioxidant, U74389F, prevents estradiol-induced depletion of hypothalamic
  620. beta-endorphin in adult female rats.</strong> Schipper HM; Desjardins GC; Beaudet A; Brawer JR. Brain
  621. Res, 1994 Jul 25, 652:1, 161-3 <strong>
  622. "A single intramuscular injection of 2 mg estradiol valerate (EV) results in neuronal degeneration and
  623. beta-endorphin depletion in the hypothalamic arcuate nucleus of adult female rats."</strong>
  624. </p>
  625. <p>
  626. J Neurochem 1998 Sep;71(3):1187-93 <strong>
  627. Energy dependency of glucocorticoid exacerbation of gp120 neurotoxicity.</strong>
  628. Brooke SM, Howard SA, Sapolsky RM "The HIV envelope glycoprotein, gp120, a well documented neurotoxin, may
  629. be involved in AIDS-related dementia complex. gp120 works through an NMDA receptor- and calcium-dependent
  630. mechanism to damage neurons. We have previously demonstrated that both natural and synthetic glucocorticoids
  631. (GCs) exacerbate gp120-induced neurotoxicity and calcium mobilization in hippocampal mixed cultures. GCs,
  632. steroid hormones secreted during stress, are now shown to work in conjunction with gp120 to decrease ATP
  633. levels and to work synergistically with gp120 to decrease the mitochondrial potential in hippocampal
  634. cultures. <strong>
  635. Furthermore, energy supplementation blocked the ability of GCs to worsen gp120's effects on neuronal
  636. survival and calcium mobilization.</strong> A GC-induced reduction in glucose transport in hippocampal
  637. neurons, as previously documented, may contribute to this energetic dependency. These results may have
  638. clinical significance, considering the common treatment of severe cases of Pneumocystis carinii pneumonia,
  639. typical of HIV infection, with large doses of synthetic GCs."
  640. </p>
  641. <p>
  642. Acta Otolaryngol Suppl (Stockh) 1990;476:32-6. <strong>Glutamate neurotoxicity in the cochlea: a possible
  643. consequence of ischaemic or anoxic conditions occurring in ageing.</strong>
  644. Pujol R, Rebillard G, Puel JL, Lenoir M, Eybalin M, Recasens M.
  645. </p>
  646. <p>
  647. Br J Pharmacol 1996 Jan;117(1):189-95.<strong>
  648. Metabotropic glutamate receptors, transmitter output and fatty acids: studies in rat brain slices.
  649. </strong>Lombardi G, Leonardi P, Moroni F. "The requirement of both unsaturated fatty acids and 1S,3R-ACPD
  650. in the facilitation of transmitter exocytosis may play an important role in the regulation of synaptic
  651. plasticity."
  652. </p>
  653. <p>
  654. Adv Exp Med Biol 1992;318:147-58 <strong>
  655. A role for the arachidonic acid cascade in fast synaptic modulation: ion channels and transmitter uptake
  656. systems as target proteins.</strong>
  657. Volterra A, Trotti D, Cassutti P, Tromba C, Galimberti R, Lecchi P, Racagni G. "Recent evidence indicates
  658. that arachidonic acid (AA) and its metabolites play a fast messenger role in synaptic modulation in the
  659. CNS." "Other types of K+ channels in vertebrate excitable cells have been found to be<strong>
  660. sensitive to arachidonic acid, lipoxygenase products, and polyunsaturated fatty acids (PUFA). In the
  661. mammalian CNS, arachidonic acid is released upon stimulation of N-methyl-D-aspartate (NMDA)-type
  662. glutamate receptors." "Polyunsaturated fatty acids mimic arachidonate with a rank of potency parallel to
  663. the degree of unsaturation. Since the effect of glutamate on the synapses is terminated by diffusion and
  664. uptake, a slowing of the termination process may potentiate glutamate synaptic efficacy. However,
  665. excessive extracellular accumulation of glutamate may lead to neurotoxicity."
  666. </strong>
  667. </p>
  668. <p>
  669. J Neurochem 1999 Jan;72(1):129-38<strong>. Transient inhibition of glutamate uptake in vivo induces
  670. neurodegeneration when energy metabolism is impaired.
  671. </strong>
  672. Sanchez-Carbente MR, Massieu L<strong>. </strong>
  673. "Impairment of glutamate transport during ischemia might be related to the elevation of the extracellular
  674. concentration of glutamate and ischemic neuronal damage. Additionally, impairment of energy metabolism in
  675. vivo leads to neurodegeneration apparently mediated by a secondary excitotoxic mechanism. In vitro
  676. observations show that glucose deprivation and inhibition of energy metabolism exacerbate the toxic effects
  677. of glutamate." <strong>
  678. "Our results show that glutamate uptake inhibition leads to marked neuronal damage in energy-deficient
  679. rats but not in intact animals...."</strong>
  680. </p>
  681. <p>
  682. J Neurochem 1998 Nov;71(5):1993-2005. <strong>
  683. Glia modulate NMDA-mediated signaling in primary cultures of cerebellar granule cells.</strong>
  684. Beaman-Hall CM, Leahy JC, Benmansour S, Vallano ML "Nordihydroguaiaretic acid, a lipoxygenase inhibitor,
  685. blocked NMDA-mediated toxicity in astrocyte-poor cultures, raising the possibility<strong>
  686. that glia effectively reduce the accumulation of highly diffusible and toxic arachidonic acid
  687. metabolites in</strong> neurons. Alternatively, glia may alter neuronal development/phenotype in a
  688. manner that selectively reduces susceptibility to NR-mediated toxicity."
  689. </p>
  690. <p>
  691. J Neurosci 1997 Dec 1;17(23):9060-7<strong>. Pyruvate protects neurons against hydrogen peroxide-induced
  692. toxicity.
  693. </strong>
  694. Desagher S, Glowinski J, Premont J<strong>. "Pyruvate strongly protected neurons against both H2O2 added to
  695. the external medium and H2O2 endogenously produced through the redox cycling of the experimental quinone
  696. menadione. The neuroprotective effect of pyruvate appeared to result rather from the ability of
  697. alpha-ketoacids to undergo nonenzymatic decarboxylation in the presence of H2O2 than from an improvement
  698. of energy metabolism. Indeed, several other alpha-ketoacids, including alpha-ketobutyrate, which is not
  699. an energy substrate, reproduced the neuroprotective effect of pyruvate. In contrast, lactate, a neuronal
  700. energy substrate, did not protect neurons from H2O2."</strong> "Together, these results indicate that
  701. pyruvate efficiently protects neurons against both exogenous and endogenous H2O2. Its low toxicity and its
  702. capacity to cross the blood-brain barrier open a new therapeutic perspective in brain pathologies in which
  703. H2O2 is involved."<strong> </strong>
  704. </p>
  705. <p>
  706. J Neurosci 1998 Jan 1;18(1):156-63<strong>. Neuroprotective effects of creatine and cyclocreatine in animal
  707. models of Huntington's disease.
  708. </strong>Matthews RT, Yang L, Jenkins BG, Ferrante RJ, Rosen BR, Kaddurah-Daouk R, Beal MF<strong>
  709. .
  710. </strong>
  711. </p>
  712. <p>
  713. M. C. Diamond, <strong><em>Enriching Heredity: The Importance of the Environment on the Anatomy of the
  714. Brain.</em></strong> Free Press, N.Y., 1988.
  715. </p>
  716. <p>
  717. C. Finch and L. Hayflick, <strong><em>Handbook of the Biology of Aging.</em></strong>
  718. Van Nostrand Reinhold, N.Y., 1977.
  719. </p>
  720. <p>
  721. Swanson RA <strong>Physiologic coupling of glial glycogen metabolism to neuronal activity in brain.</strong>
  722. Can J Physiol Pharmacol, 1992, 70 Suppl:, S138-44. Brain glycogen is localized almost exclusively to glia,
  723. where it undergoes continuous utilization and resynthesis. We have shown that glycogen utilization increases
  724. during tactile stimulation of the rat face and vibrissae.<strong>
  725. Conversely, decreased neuronal activity during hibernation and anesthesia is accompanied by a marked
  726. increase in brain glycogen content</strong>. These observations support a link between neuronal activity
  727. and glial glycogen metabolism. The energetics of glycogen metabolism suggest that glial glycogen is
  728. mobilized to meet increased metabolic demands of glia rather than to serve as a substrate for neuronal
  729. activity. An advantage to the use of glycogen may be the potentially faster generation of ATP from glycogen
  730. than from glucose. Alternatively, glycogen could be utilized if glucose supply is transiently insufficient
  731. during the onset of increased metabolic activity. Brain glycogen may have a <strong>dynamic role as a buffer
  732. between the abrupt increases in focal metabolic demands that occur during normal brain activity and the
  733. compensatory changes in focal cerebral blood flow or oxidative metabolism.</strong>
  734. </p>
  735. <p>
  736. <strong>"Free fatty acids activate the hypothalamic-pituitary-adrenocortical axis in rats."
  737. </strong>
  738. Widmaier EP; Rosen K; Abbott B. <em>Endocrinology,</em>
  739. <strong> </strong>
  740. 1992 Nov, 131:5, 2313-8. "Intravenous administration of Intralipid 10% increases blood levels of essential
  741. free fatty acids." "Since corticosterone, the final secretory product of the rat
  742. hypothalamic-pituitary-adrenocortical (HPA) axis, is also lipolytic, we tested the hypothesis that FFA would
  743. inhibit the HPA axis." "At 60 min, plasma ACTH levels were significantly elevated to over 1500 pg/ml in
  744. Intralipid-infused rats, but were unchanged in saline controls. <strong>This dose of Intralipid increased
  745. corticosterone levels by nearly 20-fold at 120 min. At 180 min, corticosterone levels were still
  746. significantly greater</strong> than those in saline controls. Lower doses of Intralipid also
  747. significantly elevated both FFA and corticosterone levels, but by 180 min, levels of both were similar to
  748. those in controls." "The results suggest that high circulating FFA levels activate, rather than inhibit, the
  749. HPA axis in rats. Since stress activates glucocorticoid production and<strong>
  750. increases FFA levels due to lipolysis, it is possible that FFA and the HPA axis constitute a previously
  751. unrecognized positive feedback loop."</strong>
  752. </p>
  753. <p>
  754. <strong>"Impairment of glucose disposal by infusion of triglycerides in humans: role of glycemia,"
  755. </strong>
  756. Felley CP; Felley EM; van Melle GD; Frascarolo P; J"quier E; Felber JP, Am J Physiol, 1989 Jun, 256:6 Pt 1,
  757. E747-52. <strong>"These results suggest the existence of physiological regulatory mechanisms by which 1) the
  758. rise in plasma free fatty acid inhibits both oxidative and nonoxidative glucose disposal, and 2) the
  759. rise in glycemia stimulates predominantly nonoxidative glucose disposal."</strong>
  760. </p>
  761. <p>
  762. Nature 1998 Jan 15;391(6664):281-5<strong>. Prostaglandins stimulate calcium-dependent glutamate release in
  763. astrocytes.</strong>
  764. Bezzi P, Carmignoto G, Pasti L, Vesce S, Rossi D, Rizzini BL, Pozzan T, Volterra A<strong>.
  765. </strong>Astrocytes in the brain form an intimately associated network with neurons. They respond to
  766. neuronal activity and synaptically released glutamate by raising intracellular calcium concentration
  767. ([Ca2+]i), which could represent the start of back-signalling to neurons.<strong>
  768. Here we show that coactivation of the AMPA/kainate and metabotropic glutamate receptors (mGluRs) on
  769. astrocytes stimulates these cells to release glutamate through a Ca2+-dependent process mediated by
  770. prostaglandins. Pharmacological inhibition of prostaglandin synthesis prevents glutamate release,
  771. whereas application of prostaglandins (in particular PGE2) mimics and occludes the releasing action of
  772. GluR agonists. PGE2 promotes Ca2+-dependent glutamate release from cultured astrocytes and also from
  773. acute brain slices under conditions that suppress neuronal exocytotic release.
  774. </strong>When applied to the CA1 hippocampal region, PGE2 induces increases in [Ca2+]i both in astrocytes
  775. and in neurons. The [Ca2+]i increase in neurons is mediated by glutamate released from astrocytes, because
  776. it is abolished by GluR antagonists.<strong>
  777. Our results reveal a new pathway of regulated transmitter release from astrocytes and outline the
  778. existence of an integrated glutamatergic cross-talk between neurons and astrocytes in situ that may play
  779. critical roles in synaptic plasticity and in neurotoxicity.
  780. </strong>
  781. </p>
  782. <p>
  783. Prog Neurobiol 1998 Jan;54(1):99-125<strong>. Microglia as effector cells in brain damage and repair: focus
  784. on prostanoids and nitric oxide.
  785. </strong>Minghetti L, Levi G.<strong> </strong>
  786. "The present article deals with two classes of compounds that activated microglial cells can produce in
  787. large amounts: prostanoids (that derive from arachidonic acid through the cyclooxygenase pathway), and
  788. nitric oxide (that is synthesized from arginine by nitric oxide synthase). Prostanoids and nitric oxide have
  789. a number of common targets, on which they may exert similar or opposite actions, and have a crucial role in
  790. the regulation of inflammation, immune responses and cell viability. Their synthesis can massively increase
  791. when the inducible isoforms of cyclooxygenase and nitric oxide synthase are expressed."
  792. </p>
  793. <p>
  794. In Vitro Cell Dev Biol Anim 1998 Mar;34(3):265-74<strong>. Prostaglandins act as neurotoxin for
  795. differentiated neuroblastoma cells in culture and increase levels of ubiquitin and beta-amyloid.
  796. </strong>Prasad KN, La Rosa FG, Prasad JE<strong>. </strong>
  797. "Although chronic inflammatory reactions have been proposed to cause neuronal degeneration associated with
  798. Alzheimer's disease (AD), the role of prostaglandins (PGs), one of the secretory products of inflammatory
  799. reactions, in degeneration of nerve cells has not been studied. Our initial observation that <strong
  800. >PGE1-induced differentiated neuroblastoma (NB) cells degenerate in vitro more rapidly than those inducedby
  801. RO20-1724, an inhibitor of cyclic nucleotide phosphodiesterase, has led us to postulate that PGs act as
  802. a neurotoxin.</strong> This study has further investigated the effects of PGs on differentiated NB cells
  803. in culture. Results showed that PGA1 was more effective than PGE1 in causing degeneration of differentiated
  804. NB cells as shown by the cytoplasmic vacuolation and fragmentation of soma, nuclei, and neurites. Because
  805. increased levels of ubiquitin and beta-amyloid have been implicated in causing neuronal degeneration, we
  806. studied the effects of PGs on the levels of these proteins during degeneration of NB cells in vitro...."
  807. "Results showed that PGs increased the intracellular levels of ubiquitin and beta-amyloid prior to
  808. degeneration, whereas the degenerated NB cells had negligible levels of these proteins. <strong>These data
  809. suggest that PGs act as external neurotoxic signals</strong> which increase levels of ubiquitin and
  810. beta-amyloid that represent one of the intracellular signals for initiating degeneration of nerve cells."
  811. </p>
  812. <p>
  813. Brain Res Bull 1998 Apr;45(6):637-40. <strong>
  814. The fatty acid composition of maternal diet affects the response to excitotoxic neural injury in
  815. neonatal rat pups.</strong>Valencia P, Carver JD, Wyble LE, Benford VJ, Gilbert-Barness E, Wiener DA,
  816. Phelps C<strong>
  817. Fatty acids and their derivatives play a role in the response to neural injury.</strong> The effects of
  818. prenatal and postnatal dietary fatty acid composition on excitotoxic neural injury were investigated in
  819. neonatal rat pups."
  820. </p>
  821. <p>
  822. Proc Soc Exp Biol Med 1998 Nov;219(2):120-5<strong>. Prostaglandins as putative neurotoxins in Alzheimer's
  823. disease.</strong> Prasad KN, Hovland AR, La Rosa FG, Hovland PG<strong>. </strong>
  824. "Chronic inflammatory reactions in the brain appear to be one of the primary etiological factors in the
  825. pathogenesis of Alzheimer's disease (AD). This is supported by the fact that the secretory products of
  826. inflammatory reactions, which include cytokines, complement proteins, adhesion molecules, and free radicals,
  827. are neurotoxic. We have recently reported that prostaglandins (PGs), which are also released during
  828. inflammatory reactions, cause rapid degenerative changes in differentiated murine neuroblastoma cells (NB)
  829. in culture." "The mechanisms underlying Abeta-induced neuronal degeneration have been under intense
  830. investigation, and several mechanisms of action have been proposed. We postulate that PG-induced elevation
  831. of Abeta may lead to an increased binding of Abeta to the 20S proteasome, resulting in a reduction of 20S
  832. proteasome-mediated degradation of ubiquitin-conjugated proteins. This is predicted to lead to an increase
  833. in an accumulation of abnormal proteins, which ultimately contribute to neuronal degeneration and death.
  834. Based on our hypothesis and on studies published by others, we propose that a combination of nonsteroidal
  835. anti-inflammatory drugs, which inhibit the synthesis of PGs, and antioxidant vitamins, which quench free
  836. radicals and both of which have been recently reported to be of some value in AD treatment when
  837. used-individually, may be much more effective in the prevention and treatment of AD than the individual
  838. agents alone."
  839. </p>
  840. <p>
  841. Mol Chem Neuropathol 1998 May;34(1):79-101<strong>. Effects of EGb 761 on fatty acid reincorporation during
  842. reperfusion following ischemia in the brain of the awake gerbil.
  843. </strong>
  844. Rabin O, Drieu K, Grange E, Chang MC, Rapoport SI, Purdon AD<strong>. </strong>
  845. </p>
  846. <p>
  847. <strong>Regulation of arcuate nucleus synaptology by estrogen.</strong> Leedom L; Lewis C; Garcia-Segura LM;
  848. Naftolin F. Ann N Y Acad Sci, 1994 Nov 14, 743:, 61-71 "Estrogen modulates the synaptology of the
  849. hypothalamic arcuate nucleus during sexual differentiation of the rat brain in both males and females. In
  850. <strong>
  851. males, testosterone of gonadal origin is converted to estrogen in the brain</strong> by an enzyme,
  852. aromatase, which is also present in females. The exposure of the male's hypothalamus to relatively high
  853. levels of estrogen (following a perinatal testosterone surge) leads to the development of a pattern of
  854. synaptogenesis<strong>
  855. which does not support an estrogen-induced gonadotrophin surge in the adult.</strong> In female rats,
  856. hypothalamic development <strong>occurs with permissively low levels</strong> of estrogen, enabling a
  857. midcycle estrogen-induced gonadotrophin surge and ovulation in adulthood. During adult reproductive life in
  858. female rats, circulating estrogen modulates the synaptology of the arcuate nucleus. <strong>The most
  859. physiological example of this is the 30-50% loss of axosomatic synapses following the preovulatory
  860. estrogen surge on diestrus-proestrus.</strong>
  861. Studies on post-synaptic membranes of the arcuate nucleus reveal sex differences in membrane organization
  862. and protein content which are estrogen-dependent. <strong>
  863. Estrogen apparently stimulates endocytosis of areas of post-synaptic membrane that are dense with small
  864. intramembranous protein particles, resulting in a reduction in the number of small intramembranous
  865. particles. This also appears to be the physiologic mechanism of neuronal changes in females during the
  866. estrus cycle.</strong> Repeated exposure to preovulatory levels of estrogen may lead to an age-related
  867. decline in reproductive capacity in female rats. Aging females lose the estrogen-induced gonadotrophin surge
  868. responsible for ovulation. <strong>This loss of function may result from a cumulative estrogen effect during
  869. the repeated ovarian cycles which results in a reorganization of the synaptology</strong> on which
  870. regulates the estrogen-induced gonadotrophin surge." ". . .recent research has shown that GABA, the
  871. monoamines, and several neuropeptides are participants in the estrogen-sensitive network which regulates
  872. GNRH secretion. In this regard, present work shows estrogen-induced changes in GABA and dopamine synapses in
  873. the arcuate nucleus."
  874. </p>
  875. <p>
  876. <strong>17 beta Estradiol-induced increase in brain dopamine D-2 receptor: antagonism by MIF-1.</strong>
  877. <strong>
  878. Rajakumar G</strong>; Chiu P; Chiu S; Johnson RL; <strong>Mishra RK</strong> Department of Psychiatry,
  879. Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada. Peptides, 1987 Nov-Dec, 8:6,
  880. 997-1002 Animal behavioral and neurochemical studies implicate dopaminergic systems<strong>
  881. in the neurological sequelae induced by estrogen.</strong> In the present study, we demonstrated for the
  882. first time that MIF-1, a neuropeptide unrelated to classical dopamine agonists, when given prior to,
  883. concurrently with, and after 17 beta-estradiol, antagonized significantly the estrogen-induced increase in
  884. the<strong> density of dopamine D-2 receptor</strong> both in the striatum and the mesolimbic area of male
  885. rat brain. The current findings have implications for the prophylactic and therapeutic potential for MIF-1
  886. in <strong>extrapyramidal motor disorders caused by estrogen imbalance in humans.</strong>
  887. </p>
  888. <p>
  889. Eur J Clin Invest 1984 Dec;14(6):431-4 <strong>
  890. Effect of ovulation on haem metabolism in rabbits.</strong> Lindahl J, Werner B, Lerner R<strong>. "To
  891. investigate the origin of the cyclic changes in the rate of endogenous carbon-monoxide production (nCO)
  892. during the menstrual cycle, haem turnover was determined before and after chorion gonadotropic
  893. hormone-induced ovulation in six female rabbits. 14C-labelled delta-aminolevulinic acid and glycine were
  894. administered and the excretion rate of 14CO (A14CO) was measured for determination of hepatic
  895. and</strong>
  896. bone-marrow haem turnover, respectively." <strong>
  897. ". . . nCO was increased 34% (P less than 0.05) during the post-ovulation period. As the increase in
  898. 'unassigned' haem turnover was small and may be unaccompanied by a contemporary increase in bilirubin/CO
  899. production, it was concluded that the increase in nCO during the post-ovulation period essentially
  900. depends on increased destruction of circulating red cells in the rabbit."</strong>
  901. </p>
  902. <p>
  903. J Neurotrauma 1993 Winter;10(4):373-84. <strong>
  904. Beneficial effect of the nonselective opiate antagonist naloxone hydrochloride and the
  905. thyrotropin-releasing hormone (TRH) analog YM-14673 on long-term neurobehavioral outcome following
  906. experimental brain injury in the rat.
  907. </strong>
  908. McIntosh TK, Fernyak S, Hayes RL, Faden AI
  909. </p>
  910. <p>
  911. J Neurosci 1990 Nov;10(11):3524-30. <strong>
  912. Opiate antagonist nalmefene improves intracellular free Mg2+, bioenergetic state, and neurologic outcome
  913. following traumatic brain injury in rats.
  914. </strong>
  915. Vink R, McIntosh TK, Rhomhanyi R, Faden AI. "Treatment of CNS trauma with the opiate antagonist naloxone
  916. improves outcome, though the mechanisms of action remain speculative."
  917. </p>
  918. <p>
  919. Brain Res 1989 Mar 20;482(2):252-60. <strong>
  920. Magnesium protects against neurological deficit after brain injury.</strong>
  921. McIntosh TK, Vink R, Yamakami I, Faden AI.
  922. </p>
  923. <p>
  924. Adv Neurol 1988;47:531-46. <strong>
  925. Role of thyrotropin-releasing hormone and opiate receptor antagonists in limiting central nervous system
  926. injury.</strong> Faden AI. "Opiate antagonists, including receptor antagonists and physiologic
  927. antagonists, have been shown to produce beneficial effects in a variety of models of CNS injury and in a
  928. variety of species. Opiate antagonists improve spinal cord blood flow, electrical conduction of the spinal
  929. cord, pathological changes, and motor recovery following traumatic spinal cord injury in cats. TRH appears
  930. to be superior to naloxone in this regard, although direct comparisons between receptor-selective opiate
  931. receptor antagonists and TRH have not been made."
  932. </p>
  933. <p>
  934. Exp Neurol 1994 Sep;129(1):64-9.<strong>Progesterone facilitates cognitive recovery and reduces secondary
  935. neuronal loss caused by cortical contusion injury in male rats.</strong> Roof RL, Duvdevani R, Braswell
  936. L, Stein DG.
  937. </p>
  938. <p>
  939. Exp Neurol 1996 Apr;138(2):246-51. <strong>
  940. Progesterone rapidly decreases brain edema: treatment delayed up to 24 hours is still effective.</strong
  941. > Roof RL, Duvdevani R, Heyburn JW, Stein DG.
  942. </p>
  943. <p>
  944. Mol Chem Neuropathol 1997 May;31(1):1-11. <strong>
  945. Progesterone protects against lipid peroxidation following traumatic brain injury in rats.</strong> Roof
  946. RL, Hoffman SW, Stein DG.
  947. </p>
  948. <p>
  949. Jiang N, et al. <strong>Progesterone is neuroprotective after transient middle cerebral artery occlusion in
  950. male rats.</strong> Brain Res. 1996 Sep 30;735(1):101-7.
  951. </p>
  952. <p>
  953. Roof RL, et al. <strong>Progesterone rapidly decreases brain edema: treatment delayed up to 24 hours is
  954. still effective.</strong> Exp Neurol. 1996 Apr;138(2):246-51.
  955. </p>
  956. <p>
  957. Duvdevani R, et al. <strong>Blood-brain barrier breakdown and edema formation following frontal cortical
  958. contusion: does hormonal status play a role?</strong> J Neurotrauma. 1995 Feb;12(1):65-75.
  959. </p>
  960. <p>
  961. Exp Neurol 1997 Dec;148(2):453-63. <strong>
  962. Endogenous repair after spinal cord contusion injuries in the rat.
  963. </strong>
  964. Beattie MS, Bresnahan JC, Komon J, Tovar CA, Van Meter M, Anderson DK, Faden AI, Hsu CY, Noble LJ, Salzman
  965. S, Young W.<strong>
  966. "In addition to signs of regeneration, we noted evidence for the proliferation of cells located in the
  967. ependymal zone surrounding the central canal at early times following contusion injuries."</strong>
  968. </p>
  969. © Ray Peat Ph.D. 2009. All Rights Reserved. www.RayPeat.com
  970. </body>
  971. </html>